External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology 2026 ASCO® Annual Meeting
Roche and Genentech at

2026 ASCO® Annual Meeting

May 29 - June 02
Chicago, USA / Virtual (Hybrid)
am.asco.org
We will be contributing to topics related to
Oncology Haematology
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
07:12 PM
Duration 6mins Chicago, USA
Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial
Harkins RA, Harris W, Green M, Herrera AF, Jardin F, Lenz G, Morschhauser F, Sugidono M, Yan M, Batlevi CL, Flowers CR, Jiang Y
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 180mins Chicago, USA
Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC)
Amylou C. Dueck; Briant Fruth; Anke C. Reinacher-Schick; Walter Peters; Robert J. Behrens; Christopher Hanyoung Lieu; Khalid Matin; Deirdre J. Cohen; Samara L. Potter; Wendy L. Frankel; Ardaman Shergill; Dennis Hsu; Dirk Arnold; Tyler Zemla; Clare A. Gatten; Peter Trask; Eileen M. O'Reilly; Jeffrey A. Meyerhardt; Fang-Shu Ou; Frank A. Sinicrope
Oncology | Colon cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Achieving epidemiologically representative enrollment and social determinants of health the Phase III evERA Breast Cancer Study (NCT05306340)
Gregory Vidal, Hope Rugo, Ricki Fairley, Valarie Worthy, Amy Tiersten, Katherine Tkaczuk, Michael Danso, Lasika Seneviratne, Ines Sanchez-Rivera, Jeffrey Neidhart, Ibrahim Abbass, Amy Vassel, Gillian DiLallo, Lauren Davis, Georgia Dangel, Robin Herzog, Manisha Krishnamurthy, Alejandra Benitez, Thomas Stark, Erica Mayer
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:39 PM
Duration 12mins Chicago, USA
Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the Phase III lidERA BC clinical trial: Results by menopausal status
Peter Schmid, Charles E. Geyer, Jr., Miguel Martín, Sara A. Hurvitz, Kyung Hae Jung, Mothaffar F. Rimawi, Shigehira Saji, Gustavo Werutsky, Nadia Harbeck, Sherene Loi, Ernesto Pablo Korbenfeld, Isabel Blancas, Chi-Feng Chung, Rena Desai Callahan, Meilin Huang, Miranda Craft, Mona D. Shah, Tanja Badovinac Crnjevic, Pablo Diego Pérez-Moreno, Aditya Bardia
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 PM
Duration 12mins Chicago, USA
Fixed-duration glofitamab▼ monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton's tyrosine kinase inhibitor (BTKi) exposure: updated data after a 3.5-year follow-up
Karimi YH, Hutchings M,Phillips T, Trněný M, Dickinson M, Offner FC, Morschhauser F, Bachy E, Bartlett NL, Brody J, Zaucha J, Wrobel T, Gil L, Breton V, Negricea R, Kallemeijn M, Berthier A, Sellam G, Lundberg L, Carlo-Stella C
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:12 PM
Duration 12mins Chicago, USA
Mosunetuzumab▼ plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the Phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups
Budde EL, Kim W, Westin J, Maruyama D, Zhang H, Goto H, Hong H, Fesler M, Goodgame B, Li Z, Rego EM, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, Janousek M, Pham S, Batlevi CL, Wei MC
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 180mins Chicago, USA
Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA–guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC)
Joaquim Bellmunt, Thomas Powles, Jessica Grindheim, Mesut Yılmaz, Grigorios Rallis, Mahmut Gumus, Consuelo Buttigliero, Teresa Bonfill, Franco Nolè, Ho Kyung Seo, Michaela Matoušková, Iwona Skoneczna, Wim Demey, Patrizia Giannatempo, Sylvie Rottey, Damien Pouessel, Syed A. Hussain, Elizabeth E. Steinberg, Richard Price, Yohann Loriot
Oncology | Urinary Bladder Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
IMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance (1Lm) treatment (Tx) with lurbinectedin (lurbi) + atezolizumab (atezo) vs atezo in extensive-stage small cell lung cancer (ES-SCLC)
Hossein Borghaei, Luis Paz-Ares, Martin Reck, Roy S Herbst, Solange Peters, Kamalnayan Bhatt, Xiaoyan Wang, Jonathon Gable
Oncology | Small Cell Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Resistance mechanisms and efficacy of first-line alectinib and sequential treatments in advanced ALK+ NSCLC: real-world outcomes from a multicenter, observational study in Japan (ALCURE)
Hirotsugu Kenmotsu, Yasutaka Watanabe, Shoichi Itoh, Eiki Ichihara, Hiroshi Tanaka, Koichi Azuma, Ryo Arai, Shoichi Kuyama, Hiroaki Akamatsu, Kohei Otsubo, Hitomi Ajimizu, Yosuke Seto, Ken Uchibori, Hidetoshi Hayashi, Eisaku Miyauchi, Yuichi Ozawa, Naoki Ishizuka, Yuki Nakagawa, Ryohei Katayama
Oncology | Non-Small Cell Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:12 PM
Duration 6mins Chicago, USA
Transcriptomic analyses from the Phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC)
Luis Paz-Ares, Aleksandra Szczęsna, Andrzej Każarnowicz, Barzin Nabet, Bhatt Kamalnayan, Erdem Cubukcu, George Cai, Graham Brock, Hossein Borghaei, Jin Seok Ahn, Lisa Lin, Martin Reck, Minu Srivastava, Raffaele Califano, Roy Herbst, Saadettin Kilickap, Solange Peters, Stephen Liu, Vilma Graupner, Yu-Feng Wei
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 180mins Chicago, USA
Multivariable analyses (MVAs) of overall survival (OS) in the Phase 3 SUNMO, STARGLO and POLARGO trials in relapsed/refractory large B-cell lymphoma (LBCL)
Matasar M, Westin J, Abramson JS, Olszewski AJ, Pham S, Wang J, Barrett S, To I, Yin S, Batlevi C, Musick L, Lundberg L, Wei MC, Budde LE
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Fixed-duration subcutaneous (SC) mosunetuzumab▼ (Mosun) monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): interim analysis of the Phase II MorningSun study
Flinn I W, Burke JM, Tun AM, Ayed A, Biondo JML, Wu M, Hossain F, Mun Y, Farighi R, Singh A, Misleh J, Peles S, Budde EL, Villasboas JC, Sharman JP
Haematology - Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:09 PM
Duration 12mins Chicago, USA
IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev)
Arndt Vogel, Ivan Borbath, Shwetha Chiluveru, Hong Jae Chon, Yin-Hsun Feng, Natsumi Irahara, Bo Hyun Kim, Jennifer Knox, Masatoshi Kudo, Shi Li, Tim Meyer, Joong-Won Park, Shu-Kui Qin, Anila Tahiri, Yann Touchefeu, Bruno Sangro
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:00 PM
Duration 6mins Chicago, USA
Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i)
Komal L. Jhaveri, Hope S. Rugo, Sara M. Tolaney, Miguel Martín, Gregory A. Vidal, Luca Moscetti, Adam Brufsky, William J. Gradishar, Andreas Schneeweiss, Naoki Niikura, Anne Favret, Margarita Alfie, Keun Seok Lee, Sarah Khan, Kristin L. Griffiths, Lisa H. Lam, Merilin B. Feldman, Bann-mo Day, Pablo D. Pérez-Moreno, Erica L. Mayer
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 PM
Duration 180mins Chicago, USA
Safety and efficacy of ZN-A-1041, a highly blood-brain barrier (BBB)-permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial
Nancy U. Lin, Sarah Heeson, Mahesh Shivhare, Zack Cheng, Ding Zhou, Laura Hiles, Rashmi K. Murthy, Maria Gion, Angel Guerrero-Zotano, Alessandro A. Viansone, Ciara O'Brien, Weize Huang, Filippo Montemurro, Adam Knott, Ethan Zhu, Eleonora Restuccia, Carey K. Anders
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Adjuvant antibody-drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): A US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations
Paolo Tarantino, Thibaut Sanglier, Elsa Garcia Hernandez, Tijana Krnjeta Janicijevic, Ibrahim Abbass
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 180mins Chicago, USA
Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV)
Nicholas C. Turner, Kevin Kalinsky, Katherine E. Hutchinson, Yanling Jin, Tiffany D. Clark, Komal L. Jhaveri, Sibylle Loibl, Cristina Saura Manich, Christine Desmedt, Hans Wildiers, Seock-Ah Im, Patrick Neven, Peter Schmid, Dejan Juric, Sherene Loi, Stephanie Hilz, Thomas J. Stout
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:45 PM
Duration 12mins Chicago, USA
Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the Phase III persevERA BC trial
Nicholas C. Turner, Komal L. Jhaveri, Aditya Bardia, Naoki Niikura, Meritxell Bellet, Carlos H. Barrios, Véronique Diéras, Seock-Ah Im, Volkmar Mueller, Erwei Song, Jorge Luis Martinez Rodriguez, Igor Bondarenko, Mabel A. Mardones, Ching-Wei Chang, Maria Louka, Miranda Craft, Pablo D. Pérez-Moreno, Monika Patre, Sherene Loi
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.